Pfizer Deal Sparks Pharma Rally; Sun Pharma, Lupin Share Price Gain Up to 4%

Shares of pharmaceutical companies surged in early trade after Pfizer announced an agreement with the US administration. Pfizer’s NSE stock jumped 8% to ₹5,442. Other pharma firms like Lupin, Eris Lifesciences, Sun Pharma, Laurus Labs, Piramal Pharma, Biocon, Granules India, and Suven Lifesciences rose 2–4%.

Market Performance

Intra-day, the Nifty Pharma and BSE Healthcare indices gained 1% each, outperforming the broader Nifty 50 and BSE Sensex, which were up 0.1–0.12%. However, over the past week, the BSE Healthcare index fell 2.6%, compared with a 1.8% decline in the benchmark indices.

What Triggered the Rally

Pfizer-US agreed to lower prices on select drugs in exchange for tariff relief. Under the deal, Pfizer will provide certain medicines at an average 50% discount through the new TrumpRx platform launching in 2026. The agreement also offers a 3-year exemption from potential pharmaceutical tariffs under the US Section 232 probe.

Implications for Indian Pharma

• Contract Development and Manufacturing Organisation (CDMO) companies with US plants may benefit.
• Pure-play generics like Ajanta Pharma, Alkem, and Marksans are largely unaffected. Firms with both branded and generic portfolios, such as Sun Pharma, Dr. Reddy’s, and Cipla, face moderate revenue and margin risks but have mitigation through US manufacturing.

Also Read: Check the list of Stock Market Holidays in 2025!

Conclusion

The Pfizer-US deal provided a short-term boost for pharma stocks and could shape pricing and tariff strategies for Indian companies with US exposure. Investors should watch how other firms respond and whether more agreements follow.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.